Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease

Tomaso Gnecchi-Ruscone, Roberto Lorenzoni, Duncan Anderson, Nigel Legg, Dimitri Tousoulis, Paul D O B Winter, Adam Crisp, Paolo G. Camici

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of intravenous ergotamine (0.25 mg) on basal and hyperemic (dipyridamole) myocardial blood flow (MBF), measured with positron emission tomography and H 2/ 15O, were assessed in 15 migraineurs in a double-blind, randomized, placebo controlled, cross-over study. Ergotamine produced a 27% reduction in hyperemic MBF (2.62 ± 0.11 vs 3.72 ± 1.05 ml · min -1 2. g - 1; p -1g -1; p

Original languageEnglish
Pages (from-to)1165-1168
Number of pages4
JournalThe American Journal of Cardiology
Volume81
Issue number9
DOIs
Publication statusPublished - May 1 1998

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease'. Together they form a unique fingerprint.

Cite this